Table 2 Predictors of switching from TDF to TAF
From: Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort
Multivariable Analysis | ||||
|---|---|---|---|---|
Variable | N (%) | Switched (%) | Adjusted odds ratio (95% CI) | P |
Male sex | 3′645 (72.7) | 2′102 (57.7) | 1.27 (1.07–1.50) | 0.01 |
Age > 50 years | 2′235 (44.6) | 1′413 (63.2) | 1.43 (1.23–1.66) | < 0.001 |
African origin | 789 (15.7) | 377 (47.8) | 0.83 (0.67–1.01) | 0.07 |
High level education | 1′652 (33.0) | 923 (55.9) | 1.16 (1.00–1.35) | 0.05 |
CD4 < 500/μL at baselinea | 1′406 (28.1) | 754 (53.6) | 0.77 (0.66–0.90) | < 0.001 |
Follow-up in a non-tertiary care center | 2′408 (48.0) | 1′169 (48.6) | 0.56 (0.46–0.70) | < 0.001 |
Comorbidities | ||||
Chronic HBV infection | 338 (6.7) | 188 (55.6) | 0.97 (0.74–1.26) | 0.81 |
Chronic HCV infection | 624 (12.5) | 349 (55.9) | 0.66 (0.54–0.80) | < 0.001 |
Diabetes | 322 (6.4) | 202 (62.7) | 0.95 (0.71–1.26) | 0.70 |
Arterial hypertension | 2′669 (53.3) | 1′584 (59.4) | 1.21 (1.04–1.40) | 0.01 |
History of CV disease | 388 (7.7) | 243 (62.6) | 0.79 (0.61–1.03) | 0.08 |
Dyslipidemia | 2′209 (44.1) | 1′336 (60.5) | 1.09 (0.94–1.26) | 0.26 |
At least one risk factor for TDF toxicityb | 652 (13.0) | 465 (71.3) | 2.21 (1.77–2.75) | < 0.001 |
PI-based ART | 1′178 (23.5) | 855 (72.6) | 0.97 (0.81–1.16) | 0.74 |
NNRTI-based single-pill regimen | 1′978 (39.5) | 522 (26.4) | 0.11 (0.09–0.13) | < 0.001 |